Exporting Natural Health Products from India to Canada: A Practical Regulatory Guide for Indian Manufacturers

Why Indian Health Supplement Manufacturers Need a Canada-Specific Regulatory Strategy

India has a growing number of manufacturers producing vitamins, minerals, herbal products, probiotics, amino acids, sports nutrition products and other health supplements for domestic and international markets. Canada can be an attractive market, but a product legally manufactured and sold in India cannot simply be shipped to Canada and placed on the Canadian market.

In Canada, many products marketed in India as dietary supplements, health supplements or nutraceuticals may be regulated as Natural Health Products (NHPs). These products are subject to Health Canada’s requirements for product licensing, site licensing, quality, safety, efficacy, labelling and good manufacturing practices (GMP).

1. Start With Canadian Product Classification
The first step is to determine how Health Canada will classify the product. The Indian regulatory category does not automatically determine the Canadian category.
Before developing the Canadian label or shipping product, assess:
Whether the product meets the Canadian definition of an NHP
Whether all medicinal ingredients are acceptable in Canada
Whether the ingredients are permitted in the proposed form and dose
Whether the proposed claims are acceptable
Whether the product could instead be regulated as a food, cosmetic, drug or another category
How Fiducia Globus can help: We can conduct an initial Canadian regulatory assessment and identify the likely product category, key regulatory pathway and potential issues before you invest in Canadian packaging or commercialization.

2. Review Every Ingredient Against Canadian Requirements
An ingredient permitted in an Indian health supplement is not automatically acceptable for an NHP in Canada. Each medicinal ingredient should be assessed for identity, source, form, dose, conditions of use, safety considerations and applicable Health Canada requirements.
Key review points include:
Ingredient identity and nomenclature
Source and form
Medicinal ingredient quantity and daily dose
Permitted uses and claims
Applicable Health Canada monographs
Restrictions or conditions associated with the ingredient
How Fiducia Globus can help: We can review your formula ingredient-by-ingredient, identify Canadian regulatory gaps and advise on formulation or dose changes where needed.

3. Determine the Evidence Needed for a Canadian Product Licence
Most NHPs require a Health Canada product licence before they can be marketed in Canada. Licensed products receive an eight-digit Natural Product Number (NPN).
A Product Licence Application may require information such as:
Medicinal ingredients
Non-medicinal ingredients
Quantity and potency
Dosage form
Recommended use/purpose
Dose and directions
Risk information
Quality specifications
Evidence supporting safety and efficacy
Other product and manufacturing information, as applicable
How Fiducia Globus can help: We can determine the appropriate licensing strategy, prepare or coordinate the Product Licence Application (PLA), compile supporting documentation and manage regulatory correspondence through the application process.

4. Understand Canadian Site Licensing and Foreign Manufacturing Requirements
For NHPs imported into Canada, the Canadian importer must hold the appropriate Site Licence, and the foreign manufacturing site must be appropriately listed on the importer’s Site Licence. The manufacturing activities must comply with applicable Canadian GMP requirements.
A key 2026 change is that Health Canada discontinued the Foreign Site Reference Number (FSRN) process effective February 16, 2026. New FSRN applications are no longer accepted; foreign-site GMP information is integrated into the site-licensing process.
How Fiducia Globus can help: We can assess your Indian manufacturing site against Canadian NHP GMP expectations, help prepare the required documentation, coordinate with the Canadian importer and support the foreign-site information required for the Site Licence.

5. Choose the Right Canadian Importer or Market-Entry Partner
Your Canadian importer is not simply a logistics provider. The importer has important regulatory responsibilities and should understand NHP site licensing, GMP, product release, documentation, complaints, recalls and distribution requirements.
How Fiducia Globus can help: We can help define the regulatory responsibilities of the Indian manufacturer and Canadian importer and establish a practical regulatory responsibility matrix or quality agreement framework.

6. Build the Canadian Label Before Printing Packaging
Do not simply translate an Indian label into English and use it in Canada. Canadian NHP labelling requirements are specific and can differ substantially from Indian requirements.
Depending on the product, the Canadian label may need to address:
Product name and dosage form
Medicinal ingredients and quantities
Recommended use/purpose
Directions
Warnings and risk information
Net amount
Lot/batch information
Expiry date
Storage conditions
Licence holder and contact information
NPN
Required bilingual information
Product Facts Table, where applicable
How Fiducia Globus can help: We can perform a Canada-specific label review, identify mandatory elements, align the label with the authorized product information and coordinate required English/French content before artwork is finalized.

7. Plan for English and French From the Beginning
Canadian bilingual labelling requirements should be considered at the beginning of the project rather than after packaging artwork has been finalized. For applicable products, the Product Facts Table must be presented in bilingual form or as separate English and French tables.
How Fiducia Globus can help: We can identify the bilingual labelling requirements for your product and coordinate regulatory review of English and French content so that the final artwork is aligned with Canadian requirements.

8. Make Your Quality System Canada-Ready
Health Canada’s updated NHP GMP guidance took effect March 4, 2026. Indian manufacturers should review their quality systems against current Canadian expectations rather than relying solely on domestic compliance.
Areas to review include:
Raw material and supplier controls
Manufacturing and in-process controls
Finished product testing
Specifications
Batch records
Deviation and OOS investigations
CAPA
Change control
Complaints and recalls
Retention samples
Record keeping and data integrity
Stability program
How Fiducia Globus can help: We can perform a regulatory/GMP gap assessment and help develop or update SOPs, quality documentation, specifications and quality-system elements needed for the Canadian market.

9. Review Finished Product Specifications and Testing
Finished product specifications remain an important part of NHP quality compliance. Health Canada announced in June 2026 that finished product specifications no longer need to be routinely submitted with Class II and III PLAs and amendments. This is a submission-process change—not an elimination of the underlying requirement to establish and maintain appropriate specifications.
Manufacturers should ensure that specifications and testing appropriately address, as applicable:
Identity
Quantity/assay
Potency where applicable
Purity
Microbiological quality
Heavy metals and other contaminants
Other product-specific quality attributes
Validated or appropriate test methods
How Fiducia Globus can help: We can review your specifications, Certificates of Analysis and testing program for alignment with Canadian NHP requirements and identify gaps before commercial production.

10. Support the Proposed Shelf Life With Stability Data
The shelf life declared for a Canadian NHP should be scientifically supported. Stability planning should consider the formulation, packaging, storage conditions and transportation conditions relevant to the Canadian market.
How Fiducia Globus can help: We can review your existing stability data, identify gaps and help develop a stability strategy appropriate for the proposed Canadian shelf life.

11. Make Sure Your Claims Are Acceptable in Canada
Marketing claims are a frequent source of regulatory problems. A claim used legally in India or on an international website does not automatically become acceptable in Canada.
Claims should be reviewed for consistency with the authorized Canadian conditions of use, including claims relating to:
Disease treatment or prevention
Weight management
Blood sugar or cholesterol
Immunity
Pain relief
Hormonal effects
Sports performance
Other therapeutic effects
How Fiducia Globus can help: We can review proposed claims for the Canadian market and help align your website, product pages, Amazon listings, brochures and packaging with the licensed product information.

12. Prepare the Export and Import Documentation
Regulatory compliance and shipment readiness need to work together. Before the first commercial shipment, establish a document package covering the applicable product, manufacturing, testing, importer and shipping information.
How Fiducia Globus can help: We can provide an export-readiness checklist and help coordinate the regulatory documentation required for the Canadian launch and shipment process.

13. Make Sure the Commercial Product Matches the Licensed Product
The product that reaches Canada should match the formulation, specifications, manufacturing information, label and other details associated with its Canadian authorization. Changes should be assessed for their regulatory impact before implementation.
How Fiducia Globus can help: We can support change-control assessments and determine whether a proposed formulation, supplier, manufacturing, specification or labelling change may require a Canadian regulatory action.

14. Establish Post-Market Compliance Before Launch
Canadian compliance does not end when an NPN is issued. Manufacturers and Canadian partners should have processes for complaints, adverse reactions, quality issues, recalls, traceability, change control and ongoing regulatory compliance.

How Fiducia Globus can help: We can help establish or review complaint handling, adverse reaction reporting, recall, traceability, CAPA and change-control procedures and clarify responsibilities between the manufacturer and Canadian importer/licence holder.
Indian NHP Export to Canada: Pre-Launch Checklist

Product classification confirmed for Canada
Medicinal and non-medicinal ingredients reviewed
Dose and claims assessed
Canadian Product Licence/NPN strategy established
Canadian importer identified and Site Licence responsibilities confirmed
Indian manufacturing site assessed for Canadian GMP expectations
Canadian label reviewed
English/French requirements addressed
Product Facts Table assessed, where applicable
Finished product specifications established
Testing and CoA requirements reviewed
Shelf life supported by appropriate stability data
Export/import documentation prepared
Commercial product matched to the Canadian authorization
Post-market complaint, adverse reaction and recall responsibilities assigned

How Fiducia Globus Can Help Indian Manufacturers Export NHPs to Canada
Entering Canada is easier when regulatory planning starts before the product is manufactured. Fiducia Globus supports Indian manufacturers through the complete Canadian NHP market-entry pathway—from initial product assessment to licensing, labelling, GMP readiness and commercial launch.
1. Product & Ingredient Assessment: Canadian classification, ingredient review, dose and claims assessment.
2. Regulatory Strategy: Product Licence/NPN pathway, evidence strategy and regulatory gap assessment.
3. Product Licence Support: PLA preparation, documentation coordination and Health Canada correspondence.
4. GMP & Manufacturing Readiness: Canadian NHP GMP gap assessment and quality-system support.
5. Site Licence / Importer Coordination: Support for foreign manufacturing-site information and coordination with the Canadian importer.
6. Label & Claims Compliance: Canadian label review, Product Facts Table assessment and English/French requirements.
7. Quality & Stability: Specifications, testing, CoA and stability strategy review.
8. Launch Readiness: Export-readiness review, documentation and regulatory responsibility mapping.
9. Post-Market Compliance: Complaints, adverse reactions, recalls, CAPA, change control and ongoing regulatory support.

Final Thoughts
Exporting health supplements from India to Canada is not simply a matter of finding a distributor and shipping the product. For many products, Canadian market entry requires a coordinated approach covering classification, ingredients, product licensing, GMP, site licensing, labelling, quality, claims, importation and post-market compliance.
The most effective strategy is to build Canadian requirements into the product development and export plan from the beginning—not after the product has already been manufactured or the packaging has been printed.
If you are an Indian manufacturer planning to export natural health products, dietary supplements, vitamins, minerals, herbal products, probiotics or similar products to Canada, Fiducia Globus can help you assess the regulatory pathway, identify gaps and build a practical plan for Canadian market entry.

Frequently Asked Questions (FAQ)
Can Indian manufacturers export dietary supplements to Canada?
Yes, but the product must meet Canadian regulatory requirements. Many products marketed as dietary or health supplements in India may be regulated as Natural Health Products in Canada and may require a Product Licence/NPN before marketing.
Do Indian health supplements need an NPN in Canada?
Generally, an NHP must be licensed before it is marketed in Canada and receives an eight-digit Natural Product Number (NPN).
Does an Indian manufacturing licence work in Canada?
An Indian manufacturing licence does not replace Canadian requirements. The Canadian importer must hold the appropriate Site Licence, and the foreign manufacturing site must be appropriately covered under that licence and meet applicable GMP requirements.
Is an FSRN still required for Indian NHP manufacturers?
No. Health Canada discontinued the Foreign Site Reference Number process effective February 16, 2026. Foreign-site GMP information is now integrated into the site-licensing process.
Do Canadian NHP labels need French?
Applicable Canadian NHP label information generally needs to be presented in English and French, with specific requirements depending on the product and label element. Applicable Product Facts Tables must be bilingual or provided separately in English and French.
Can an Indian NHP use the same claims in Canada?
Not necessarily. Canadian claims must be assessed against the product’s Canadian authorization and applicable Health Canada requirements.

Regulatory Sources
Health Canada — Importing and Exporting Health Products for Commercial Use (GUI-0117)
Health Canada — Guidance Document: Labelling of Natural Health Products
Health Canada — Good Manufacturing Practices Guide for Natural Health Products (GUI-0158), effective March 4, 2026
Health Canada — Ending Foreign Site Reference Number Process, February 16, 2026
Health Canada — Transition from ePost Connect to LiquidFiles for Site Licence Submissions, March 30, 2026
Health Canada — Expectations for Finished Product Specifications, June 15, 2026